Once again, the Dutch online pharmacy Redcare Pharmacy delights with strong business figures. Thanks to effective cost-saving measures and the acquisition of the Swiss Mediservice, the company was able to record an unexpectedly high profit in the third quarter. The forecast for the current year was also raised in early August and has now been confirmed by the management.

This led to a positive response in the stock market, with shares climbing up to six percent shortly after opening. A trader commented on the figures as "very strong", as they not only exceeded market expectations, but also the company's own forecasts. The Baader Bank, which initially rated Redcare Pharmacy as "Buy" with a target price of 125 euros following the quarterly figures, emphasized the company's strength despite difficult macroeconomic conditions.

The company has demonstrated strong growth potential despite challenges. Market estimates have been exceeded, explaining the positive reaction from investors. Even the company's competitors, such as DocMorris, couldn't keep up with Redcare Pharmacy's strong growth. Currently, Redcare Pharmacy's share is well over four percent in the plus.

In the third quarter, Redcare Pharmacy generated revenue of approximately 476 million euros, which corresponds to a growth of 66 percent compared to the same period last year. The acquisition of the Swiss mail-order pharmacy Mediservice significantly contributed to this result, as a large part of the revenues in Switzerland is generated from prescription drugs. Even without the acquisition, the company was able to increase its growth to just under 26 percent.

In addition, there was an increased demand from customers who were also willing to spend more money on their orders. This led to an increase in active customers by 1.6 million to a total of 10.5 million.

Thanks to savings, Redcare Pharmacy also saw a strong increase in profit before interest, taxes, depreciation and amortization (Ebitda). Compared to the same period last year, this increased by more than 14 million Euros to around 15 million Euros. This corresponds to a margin of 3.2 percent, last year it was still at 0.4 percent. Thus, Redcare Pharmacy exceeded both experts' expectations and its own target of a margin of 1.5 to 3 percent for the current year.

Although the company is still reporting a loss, it has been significantly reduced compared to last year. The loss for the first nine months of the year amounts to just under 6.5 million Euros, compared to almost 68 million Euros for the same period last year. Redcare Pharmacy aims to increase revenue to 1.7 to 1.8 billion Euros for the entire year, with just under 1.3 billion Euros already achieved in the first three quarters.

The Redcare Pharmacy stock has seen strong growth so far this year, with an increase of two and a half times. Although there were two unsuccessful attempts in October to reach the year's high of just over 119 euros, the positive development of the company testifies to its strong performance. Competitors have not been able to record nearly similar strong gains since the beginning of the year.